Nuveen Asset Management’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $693K | Buy |
250,229
+47,500
| +23% | +$132K | ﹤0.01% | 2862 |
|
|
2024
Q3 | $1.06M | Buy |
202,729
+41,850
| +26% | +$219K | ﹤0.01% | 2736 |
|
|
2024
Q2 | $718K | Hold |
160,879
| – | – | ﹤0.01% | 2860 |
|
|
2024
Q1 | $1.23M | Hold |
160,879
| – | – | ﹤0.01% | 2617 |
|
|
2023
Q4 | $685K | Buy |
160,879
+23,130
| +17% | +$98.5K | ﹤0.01% | 2895 |
|
|
2023
Q3 | $579K | Hold |
137,749
| – | – | ﹤0.01% | 2797 |
|
|
2023
Q2 | $767K | Buy |
+137,749
| New | +$767K | ﹤0.01% | 2763 |
|
|
2022
Q2 | – | Sell |
-43,574
| Closed | -$172K | – | 3324 |
|
|
2022
Q1 | $172K | Buy |
43,574
+1,313
| +3% | +$5.18K | ﹤0.01% | 3213 |
|
|
2021
Q4 | $251K | Sell |
42,261
-5,401
| -11% | -$32.1K | ﹤0.01% | 3202 |
|
|
2021
Q3 | $565K | Buy |
47,662
+268
| +0.6% | +$3.18K | ﹤0.01% | 3146 |
|
|
2021
Q2 | $808K | Buy |
47,394
+26,102
| +123% | +$445K | ﹤0.01% | 3080 |
|
|
2021
Q1 | $422K | Hold |
21,292
| – | – | ﹤0.01% | 3123 |
|
|
2020
Q4 | $439K | Buy |
21,292
+4,222
| +25% | +$87.1K | ﹤0.01% | 3069 |
|
|
2020
Q3 | $449K | Buy |
+17,070
| New | +$449K | ﹤0.01% | 2982 |
|